Vevo Therapeutics

🗓 Founded 2022👥 25 employees💰 Last funded Aug 2024
Biotechnology Research🌐 vevo.ai
Website LinkedIn
Vevo Therapeutics is a biotechnology company using its in vivo drug discovery platform and next generation AI models to uncover better drugs for more patients. The company’s Mosaic platform is the first to make in vivo data generation scalable, with single-cell precision, to capture in vivo context of disease at the first step of drug discovery and to better represent patient diversity in drug response over current in vitro assays. Vevo is using Mosaic to build the world’s largest in vivo atlas of how drugs interact with patient cells and training AI models on its data to find novel targets and drugs undetectable by other technologies. Located in San Francisco, CA, Vevo was founded by a team of inventors and thought leaders who have discovered drugs for “undruggable” targets and invented novel methods in genomics, computational biology, and chemistry. Vevo is backed by leading investors at the intersection of life sciences and technology, including General Catalyst, Wing Venture Capital, Mubadala Capital, AIX Ventures, and Camford Capital. Learn more at www.vevo.ai.
4
Total investors
4
Early stage
0
Mid stage
0
Late stage
2022
Founded

Investors

4 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
United States
4
Investor activity2022–2024 · investors recorded per year
2022320241
Recent (last 2y)Earlier
Frequently asked questions
Who invested in Vevo Therapeutics?
Vevo Therapeutics has 4 investors on record on gritt.io, including 4 early-stage backers.
When did Vevo Therapeutics last raise funding?
The most recent investment in Vevo Therapeutics recorded on gritt.io was in August 2024.
When was Vevo Therapeutics founded?
Vevo Therapeutics was founded in 2022.
What industry is Vevo Therapeutics in?
Vevo Therapeutics operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.